ArticleResearch square2025
Epidemiologic Trends in Secondary Malignant Neoplasms of the Liver in the United States: A 25-Year National Study.
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Secondary malignant neoplasms of the liver (SMNL) are more common than primary liver cancers but remain understudied. This study provides the first nationwide analysis of SMNL mortality trends and disparities in the US. Methods: This study analyzed SMNL-related (ICD-10: C78.7) CDC WONDER mortality data (1999-2023), and US Cancer Statistics incidence data for adults ≥ 45 years, stratified by demographics, geography, and primary site. Age-adjusted mortality and incidence rates (AAMRs, AAIRs) and crude mortality rates (CMRs) were reported per 100,000 population. Temporal trends were analyzed using Joinpoint regression. Results: SMNL-related AAMR rose from 23.8 (1999) to 25.1 (2023). Males accounted for 51.3% of the 597,332 deaths and had higher AAMRs than females throughout. Lung (25.6%) and colon (24.6%) cancers were the leading primary sites causing SMNL-related deaths. AAIRs and AAMRs (irrespective of metastasis) declined for most primary cancers. CMRs progressively increased across each successive 10-year age group. Non-Hispanic (NH) Blacks had the highest AAMR but with a declining trend, while NH Whites saw a significant increase. West's AAMRs showed the biggest increase. Rural areas consistently had higher AAMRs. Conclusions: SMNL mortality is rising among older US adults, with disparities. Improved primary cancer survival extends the window for metastatic progression, highlighting the need for better detection and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.